Iterum Therapeutics plc (ITRM) financial statements (2020 and earlier)

Company profile

Business Address BLOCK 2 FLOOR 3, HARCOURT CENTRE
DUBLIN, 2
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments585
Cash and cash equivalents545
Short-term investments 40
Restricted cash and investments00
Receivables00
Prepaid expense11
Deferred costs2 
Other undisclosed current assets47
Total current assets:1293
Noncurrent Assets
Property, plant and equipment11
Restricted cash and investments00
Other noncurrent assets134
Total noncurrent assets:145
TOTAL ASSETS:2698
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2811
Accounts payable154
Accrued liabilities127
Taxes payable00
Debt61
Other liabilities3 
Total current liabilities:3712
Noncurrent Liabilities
Long-term debt and lease obligation813
Long-term debt, excluding current maturities813
Liabilities, other than long-term debt71
Other liabilities71
Total noncurrent liabilities:1514
Total liabilities:5226
Stockholders' equity
Stockholders' equity attributable to parent(26)72
Common stock00
Additional paid in capital209203
Accumulated deficit(235)(132)
Total stockholders' equity:(26)72
TOTAL LIABILITIES AND EQUITY:2698

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Gross profit:01
Operating expenses(102)(77)
Operating loss:(102)(77)
Nonoperating expense(1)(0)
Other nonoperating income00
Loss from continuing operations before income taxes:(103)(77)
Income tax expense(0)(0)
Net loss available to common stockholders, diluted:(103)(77)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(103)(77)
Comprehensive loss, net of tax, attributable to parent:(103)(77)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: